Skip to main content

Posts tagged with "The Dark Side"

  • Business and Markets

    The Details of Shkreli’s Fraud

    If you want to know all the details of why Martin Shkreli was indicted, and how he has become associated with securities fraud (instead of just being associated with totally unrepentant drug price hikes), then this is the article to read. Here’s a bit: The other way to sustain the lie — and the only… Read More
  • Business and Markets

    Martin Shkreli Arrested

    Word came about a half hour ago that everyone’s least favorite spokesman for the drug industry, Martin Shkreli, was arrested for securities fraud. His former company (Retrophin) has been accusing him of just that, claiming that he was illegally moving money around to cover losses in his hedge-fund activities, and it looks like Federal prosecu… Read More
  • The Dark Side

    The Magic of Peer Review

    Here’s an article at Vox about the problems with scientific peer review, and I have to say, it’s pretty accurate. After going over how it’s supposed to work for the site’s audience, and mentioning the real problems that have become more obvious over time, they wrap up like this: . . .Science would probably be better… Read More
  • The Dark Side

    Hijacking Journals for Fun and Profit. Mostly Profit.

    Not content with faking up similar-sounding journal names and web sites, some lowlifes are actually hijacking entire scientific journal domains out from under the rightful owners. John Bohannon has an alarming report here, Long ignored by the criminal underworld, academic journal websites are finally getting noticed. One reason is the sheer scale… Read More
  • The Dark Side

    More Fake Journal Sleaze

    Here’s one for the fake-journal files: Tom Spears at the Ottawa Citizen has found a shady online journal (The “Journal of Spectroscopy and Molecular Physics”) listing its whole editorial board, with names and photographs. Only problem is, the names don’t match the photos. The person listed as Managing Editor, supposedly one… Read More
  • Business and Markets

    Valeant: Bound to be a Good Explanation, Right?

    For those of you following this saga, here’s the latest from Bronte Capital, SIRF, and the Wall Street Journal on the wonderfulness that is Valeant Pharmaceuticals. Marvel at companies that aren’t supposed to be related that share phone numbers and web sites, at Valeant prescriptions being mailed all over the place, including plenty of… Read More
  • Business and Markets

    Looking Under the Valeant Pharmaceuticals Rock

    When I last discussed Valeant Pharmaceuticals, in this rather testy post, I expressed a desire for the company to get what’s coming to it. Little did I know. Valeant recently announced that they’re not planning on growing by what’s brought them along so far (the sorts of price-raising described in that post and the links… Read More
  • The Dark Side

    Scams, Attended By Frauds

    A puzzled reader sent along this notice of a meeting next month in London. It’s ostensibly on natural products, but he noted a conspicuous lack of anyone he’d ever actually heard of in the field, and the more he read into the details of the conference, the more otherworldly it seemed. He’s right. There have… Read More
  • Infectious Diseases

    The End Result of Faked Results

    Oh, man. Here’s another example of an old, sad story – just a little fakery at the beginning, and here’s what it leads to: Government prosecutors said (Dong-Pyou) Han’s misconduct dates to 2008 when he worked at Case Western Reserve University in Cleveland under professor Michael Cho, who was leading a team testing an experi… Read More
  • The Dark Side

    A Retraction, Ten Years Later

    Here’s an odd thing, noted by a reader of this site. Organic Letters has a retraction of a paper in the Baldwin group at Oxford, “Biomimetic Synthesis of Himbacine”. This Letter has been retracted, as it was found that (a) spectra of the linear precursor, compound 14, differed when its synthesis was repeated and (b) Read More